Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLe medicament du mois. Lowette, un contraceptif pour traiter l'acne de la jeune femme.
Goffin, Véronique ULg; Pierard, Claudine ULg; Pierard, Gérald ULg

in Revue Médicale de Liège (2003), 58(4), 261-3

Acne is a multifactorial disorder affecting the vast majority of adolescents and young adults. Among the therapeutic armamentum, estroprogestative contraception can be offered to young women. The choice ... [more ▼]

Acne is a multifactorial disorder affecting the vast majority of adolescents and young adults. Among the therapeutic armamentum, estroprogestative contraception can be offered to young women. The choice must, however, be carefully targeted because the estroprogestative associations do not show similar anti-acne efficacy. A new contraceptive associating 20 micrograms of ethinyl estradiol and 100 micrograms of levonorgestrel (Lowette) has proven its clinical efficacy in this indication. [less ▲]

Detailed reference viewed: 95 (2 ULg)
Full Text
Peer Reviewed
See detailLe médicament du mois. Nouvelle contraception orale combinée au valerate d'estradiol et au dienogest (Qlaira).
Gaspard, Ulysse ULg; PINTIAUX, Axelle ULg; Kridelka, Frédéric ULg

in Revue Médicale de Liège (2010), 65(12), 706-13

In combined oral contraception (OC), a drastic reduction of both ethinylestradiol and androgenic progestins mostly derived from 19 NOR testosterone, allowed to moderately reduce the adverse impact of ... [more ▼]

In combined oral contraception (OC), a drastic reduction of both ethinylestradiol and androgenic progestins mostly derived from 19 NOR testosterone, allowed to moderately reduce the adverse impact of classical combined pills on metabolism and circulation (both arterial and venous). However, the marked hepatic action of ethinylestradiol, even in small dosages, lessens the expected risk reduction. For the first time, an OC has been developed, which contains estradiol valerate (with reduced hepatic action because of lack of a 17alpha ethinyl group) with dienogest, a 19 NOR testosterone-derived nonandrogenic progestin, which powerfully inhibits endometrial proliferation. Thanks to a dynamic modulation of estrogen and progestin doses (26 active days + 2 placebo days), an adequate contraceptive effectiveness, a good cycle control and drug tolerance are achieved, similar to those obtained with a classical low-dose OC. Recent data indicate that this new combination reduces the usually observed metabolic impact. An adequate cycle control (with 20% amenorrhea) is achieved for the first time with estradiol valerate + progestin,, in opposition with prior catastrophic results with other formulations containing 17beta-estradiol. A second combination containing estradiol + nomegestrol acetate (monophasic, 24 active days + 4 placebo days) is under study and seems also to yield promising results. Of course, in-depth study of metabolic and vascular effects of these new combinations is mandatory - and ongoing. [less ▲]

Detailed reference viewed: 22 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Olmesartan medoxomil hydrochlorothiazide (Olmetec Plus ou Belsar Plus)
Lancellotti, Patrizio ULg

in Revue Médicale de Liège (2007), 62(3), 175-9

The therapeutic control of hypertension is still a global challenge and frequently requires combination therapy. Olmesartan medoxomil hydrochlorothiazide (Olmetec plus, Belsar plus) is a fixed-dose ... [more ▼]

The therapeutic control of hypertension is still a global challenge and frequently requires combination therapy. Olmesartan medoxomil hydrochlorothiazide (Olmetec plus, Belsar plus) is a fixed-dose combination of olmesartan 20 mg and hydrochlorothiazide 12.5 or 25 mg. Olmesartan is a well known angiotensin II AT1 receptor blocker characterized by a good efficacy, a fast and prolonged duration of action and a placebo-like tolerability. With the combination therapy, no significant change of pharmacokinetics of either component is observed. The fixed-dose combination results in a greater blood pressure reduction compared to monotherapy with either component. This is at least effective as or even more effective than the combination of atenolol or losartan with hydrochlorothiazide, respectively. The responder rate is about 90%. The safety and tolerability remain excellent. Beyond the antihypertensive effect, olmesartan significantly reduces vascular inflammation and the wall-to-lumen ration in arteries. The starting dose is 20/12.5 mg. [less ▲]

Detailed reference viewed: 36 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Prasugrel (Efient): puissant inhibiteur de l'activation et de l'agregation plaquettaire de la classe des thienopyridines.
LANCELLOTTI, Patrizio ULg

in Revue Médicale de Liège (2010), 65(11), 642-7

Prasugrel (Efient), a thienopyridine of third generation, is a prodrug that, like clopidogrel, requires conversion to an active metabolite before binding to the platelet P2Y12 receptor to confer ... [more ▼]

Prasugrel (Efient), a thienopyridine of third generation, is a prodrug that, like clopidogrel, requires conversion to an active metabolite before binding to the platelet P2Y12 receptor to confer antiplatelet activity. At the currently studied doses, prasugrel inhibits adenosine diphosphate-induced platelet aggregation more rapidly, more consistently, and to a greater extent than do standard and higher doses of clopidogrel. The risk of myocardial ischemic events in patients with acute coronary syndromes has been shown to be reduced by means of platelet inhibition. Dual-antiplatelet therapy with aspirin and clopidogrel has become the cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. In patients with acute coronary syndromes (TRITON-TIMI 38 trial), prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding. Subjects with diabetes mellitus tended to even have a greater reduction in ischemic events with prasugrel. In Belgium, Efient is currently reimbursed for 1 year in patients with an acute coronary syndrome and scheduled for a percutaneous coronary intervention (PCI) who present at least one of the following criteria: primary PCI for ST-elevation myocardial infarction, stent thrombosis despite treatment with clopidogrel, or diabetes mellitus. [less ▲]

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Rimonabant (Acomplia): premier antagoniste des recepteurs CB1 du systeme endocannabinoide.
Scheen, André ULg; Van Gaal, L. F.

in Revue Médicale de Liège (2008), 63(1), 50-5

Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. Clinical trials showed that, compared to placebo, rimonabant 20 mg/ day consistently increases weight loss ... [more ▼]

Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. Clinical trials showed that, compared to placebo, rimonabant 20 mg/ day consistently increases weight loss, reduces waist circumference, improves atherogenic dyslipidaemia (low HDL cholesterol, high triglycerides, high small dense LDL), diminishes insulin resistance, reduces HbA1c levels, and contributes to lower blood pressure and C-reactive protein levels. Almost half of the most important metabolic effects occur beyond weight loss, suggesting direct peripheral effects of rimonabant, especially in visceral adipose tissue as suggested by the increase in adiponectin levels. Rimonabant at a daily dose of 20 mg is indicated as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factor(s) such as type 2 diabetes or dyslipidaemia. Adverse effects concern digestive tract (nausea, mostly transient) and psychological disorders (depressed mood, anxiety), in relation to the mechanism of action of the drug. Therefore, rimonabant is contra-indicated in case of depression and/or in patients receiving antidepressants. [less ▲]

Detailed reference viewed: 194 (2 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Rosuvastatine (Crestor).
Scheen, André ULg

in Revue Médicale de Liège (2004), 59(1), 56-9

Rosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new statin is indicated for the treatment of primary hypercholesterolaemia or combined dyslipidaemia, when changes in ... [more ▼]

Rosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new statin is indicated for the treatment of primary hypercholesterolaemia or combined dyslipidaemia, when changes in dietary habits are insufficient. Direct comparative randomised clinical trials with other statins demonstrated that rosuvastatin exerts a more favourable impact on lipid profile. When compared on a mg basis to other statins, rosuvastatin is associated with a greater reduction in total and LDL cholesterol levels and a greater increase of HDL cholesterol concentration, with a similar decrease in triglyceride levels. At the usual dosage of 10 mg, rosuvastatin allowed to reduce LDL cholesterol below recommended target levels for at risk patients among almost 80% of treated individuals in phase III clinical trials. If necessary, the daily dosage may be increased to 20 mg, or up to 40 mg (maximal dose), mostly in case of severe familial hypercholesterolaemia. Safety profile is good and similar to that of other commercialised statins. Rosuvastatin is currently evaluated in an extensive programme of randomised clinical trials (Galaxy programme) in order to demonstrate its efficacy in both prevention of atherosclerosis and reduction of cardiovascular morbidity and mortality. [less ▲]

Detailed reference viewed: 211 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Saxagliptine (ONGLYZA): nouvel inhibiteur de la dipeptidylpeptidase-4 pour le traitement oral du diabete de type 2.
Scheen, André ULg

in Revue Médicale de Liège (2010), 65(9), 527-32

Saxagliptin (Onglyza) is a specific and reversible inhibitor of dipeptidylpeptidase-4 (DPP-4), which inhibits the activity of the enzyme for at least 24 hours after one single oral administration. It ... [more ▼]

Saxagliptin (Onglyza) is a specific and reversible inhibitor of dipeptidylpeptidase-4 (DPP-4), which inhibits the activity of the enzyme for at least 24 hours after one single oral administration. It increases the circulating levels of incretin hormones (GLP-1, GIP), which contributes to amplify the insulin secretory response to meals and to reduce postprandial hyperglycaemia and, subsequently, fasting glycaemia. Saxagliptin, 5 mg once daily, has been shown to be effective in patients with type 2 diabetes treated with diet alone, metformin, sulfonylurea or glitazone, with a favourable tolerance profile. Reduction in glycated haemoglobin (HbA(1c)) averaged 0.6-0.8%, without increasing the risk of hypoglycaemia or promoting weight gain. The only indication of saxagliptin that is currently reimbursed in Belgium is the treatment of patients not controlled with metformin, the oral antidiabetic agent that is recommended as first line therapy in the management of type 2 diabetes. [less ▲]

Detailed reference viewed: 127 (2 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2.
Scheen, André ULg; Van Gaal, L. F.

in Revue Médicale de Liège (2008), 63(2), 105-9

Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this ... [more ▼]

Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this secretion is abnormally low in patients with type 2 diabetes. Sitagliptin increases post-meal insulin secretion ("incretin effect) by enhancing the postprandial GLP-1 response ("incretin enhancer"), in a glucose-dependent manner. It improves glycaemic control (HbA1c) in type 2 diabetic patients treated by diet alone, by metformin, by sulfonylurea, by glitazone or by a metformin-sufonylurea combined therapy. The glucose-lowering effect is similar to that of glipizide, but with the advantage of no weight gain and no hypoglycaemic episodes. The tolerance to sitagliptin is excellent. Treatment is simple, with 100 mg once daily, without need of titration or home blood glucose monitoring. In Belgium, sitagliptin is currently reimbursed in patients with type 2 diabetes not adequately controlled with diet and metformin monotherapy. [less ▲]

Detailed reference viewed: 305 (2 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Ulipristal acetate: une contraception d'urgence etendue a 5 jours par progesterone receptor modulator (Ellaone).
Gaspard, Ulysse ULg; Kridelka, Frédéric ULg

in Revue Médicale de Liège (2010), 65(12), 700-5

Emergency contraception is a second chance for prevention of pregnancy after unprotected intercourse. Hormonal emergency contraception with levonorgestrel 1.5 mg, only provides an effective contraception ... [more ▼]

Emergency contraception is a second chance for prevention of pregnancy after unprotected intercourse. Hormonal emergency contraception with levonorgestrel 1.5 mg, only provides an effective contraception from 0 to 72 hours after intercourse with decreasing effectiveness as time elapses. It was accordingly mandatory to develop an alternative approach with a stable contraceptive efficacy and good tolerance for 5 days, knowing additionally that the estimated lifespan of sperm in the female genital tract is about 5 days. In comparative studies bearing on more than 3000 young women, the progesterone receptor modulator (PRM) ulipristal acetate, a progesterone antagonist (taken in a single dose of 30 mg), or levonorgestrel (1.5 mg) were administered. Results indicated that the PRM was as effective as levonorgestrel, or even more, kept a stable efficacy for 120 hours after an unprotected intercourse, and was well tolerated. This establishes ulipristal acetate as the new standard for hormonal emergency contraception. [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Valdecoxib (Bextra)
Scheen, André ULg; Malaise, Michel ULg

in Revue Médicale de Liège (2004), 59(4), 251-254

Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic ... [more ▼]

Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic treatment of osteoarthritis or rheumatoid arthritis (10 to 20 mg once a day) and for the treatment of primary dysmenorrhea (40 mg once a day). Valdecoxib is as efficacious as conventional non-COX-2 selective NSAIDs, but offers the advantage of a much better gastrointestinal tolerance. Valdecoxib has a prodrug that can be administered intravenously or intramuscularly (parecoxib, Dynastat) and has been developed for the short-term treatment of postsurgical pain. [less ▲]

Detailed reference viewed: 129 (1 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Vildagliptine (Galvus) et combinaison fixe vildagliptine-metformine (Eucreas) dans le traitement du diabete de type 2.
Scheen, André ULg; Paquot, Nicolas ULg

in Revue Médicale de Liège (2009), 64(3), 161-7

Vildagliptin (Galvus) is a selective inhibitor of dipeptidylpeptidase-4, an enzyme involved in the metabolism of glucagon-like peptide-1 (GLP-1) secreted by L cells of the intestine. It potentiates the ... [more ▼]

Vildagliptin (Galvus) is a selective inhibitor of dipeptidylpeptidase-4, an enzyme involved in the metabolism of glucagon-like peptide-1 (GLP-1) secreted by L cells of the intestine. It potentiates the insulin secretory response (incretin effect) by enhancing the endogenous post-prandial response of GLP-1 (incretin enhancer) in a glucose-dependent manner. Vildagliptin is indicated in the treatment of type 2 diabetes. It improves blood glucose control (HbA1c) in patients treated by diet alone, metformin, sulfonylurea, glitazone or insulin. In patients not well controlled with metformin alone, the addition of vildagliptin is as effective in reducing HbA1c as the coadministration of glimepiride or pioglitazone. Tolerance of vildagliptin is excellent, with no weight gain and no hypoglycaemic episodes. Treatment is simple, with two doses of 50 mg per day, without need of titration or home blood glucose monitoring. In Belgium, vildagliptin is currently reimbursed for the treatment of type 2 diabetes after diet failure and monotherapy with metformin. Therapy can be administered separately or by using a fixed combination vildagliptin-metformin (Eucreas), which should improve drug compliance. [less ▲]

Detailed reference viewed: 263 (2 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois: Linagliptine (Trajenta): un inhibiteur selectif de la DPP-4 a elimination renale negligeable.
SCHEEN, André ULg; Van Gaal, L. F.

in Revue Médicale de Liège (2012), 67(2), 91-7

Linagliptin (Trajenta) is a selective inhibitor of dipeptidyl peptidase-4, an enzyme that degrades two incretin hormones, GLP-1 ("Glucagon-Like Peptide-1") and GIP ("Glucose-dependent Insulinotropic ... [more ▼]

Linagliptin (Trajenta) is a selective inhibitor of dipeptidyl peptidase-4, an enzyme that degrades two incretin hormones, GLP-1 ("Glucagon-Like Peptide-1") and GIP ("Glucose-dependent Insulinotropic Polypeptide"). As other molecules belonging to this pharmacological class, linagliptin improves blood glucose control of type 2 diabetic patients, without increasing hypoglycaemic risk, without promoting weight gain and with a good clinical and biological tolerance profile. Both efficacy and safety have been demonstrated in randomized controlled trials as monotherapy or in combination with other glucose-lowering agents, independent of demographic or clinical patient's characteristics. The pharmacokinetics specificity of linagliptin comprises its biliary excretion, with low hepatic metabolism (no drug-drug interactions) and, in contrast to other gliptins, its negligible renal elimination. Because of these favourable properties, linagliptin may be used without dose adjustment (5 mg once a day) in patients with renal impairment, as well as in elderly people. [less ▲]

Detailed reference viewed: 73 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois: Olmesartan medoxomil (Belsar ou Olmetec)
Krzesinski, Jean-Marie ULg; Scheen, André ULg

in Revue Médicale de Liège (2004), 59(10), 607-611

Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of ... [more ▼]

Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of hypertension. Olmesartan is indeed an antihypertensive agent with an efficacy dependent on the dose from 10 to 40 mg. It is taken once a day, because of a long duration of action. This prodrug has a dual elimination pathway (biliary and renal). The contraindications are the same as for the other sartans. One of its main advantage, besides its rapidly observed efficacy to lower high blood pressure, is its relatively low cost within this family. It has also cardiovascular and renal protective effects. The recommended usual dosage is 20 mg/day. [less ▲]

Detailed reference viewed: 399 (9 ULg)
Peer Reviewed
See detailLe médicament parmi les thérapies relationnelles : Enquête et réflexions.
David, Claire; WAUTHY, Jacques ULg; Vaulet, Véronique et al

in Revue des Hôpitaux de Jour Psychiatriques et des Thérapies Institutionnelles (2001)

Detailed reference viewed: 21 (5 ULg)
See detailLe médicament, la fourrure et le bâti. Le castor et ses modes d'existence
Strivay, Lucienne ULg

Article for general public (2011)

Detailed reference viewed: 46 (8 ULg)
Peer Reviewed
See detailMédicaments anti-asthmatiques. De la pharmacologie à la clinique
Louis, Renaud ULg; Radermecker, Maurice ULg

in Revue Médicale de Liège (1991), 46(2), 58-81

Detailed reference viewed: 26 (1 ULg)
Full Text
Peer Reviewed
See detailLes médicaments estampillés dans la littérature médicale latine
Marganne, Marie-Hélène ULg

in Defosse, Pol (Ed.) Hommages à Carl Deroux. II. Prose et linguistique, médecine (2002)

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailLes médicaments estampillés dans le Corpus galénique
Marganne, Marie-Hélène ULg

in Debru, Armelle (Ed.) Galen on Pharmacology. Philosophy, History and Medicine. Proceedings of the Vth International Galen Colloquium, Lille, 16-18 March 1995 (1997)

Detailed reference viewed: 51 (5 ULg)
Peer Reviewed
See detailMedicaments et grossesse.
Scheen, André ULg

in Revue Médicale de Liège (1999), 54(5), 409-14

Since the dramatic observations of fetal abnormalities associated to thalidomide use during pregnancy, the risk of malformations when prescribing drugs in pregnant women is a well-known problem, among the ... [more ▼]

Since the dramatic observations of fetal abnormalities associated to thalidomide use during pregnancy, the risk of malformations when prescribing drugs in pregnant women is a well-known problem, among the public as well as among medical doctors. However, the complexity of the problem, the lack of robust scientific data and the emotional context characterizing this period make the prescription of medications to a pregnant woman a difficult task for every people involved in health care, the pharmacist, the general practitioner and even the gynaecologist. [less ▲]

Detailed reference viewed: 28 (2 ULg)